InvestorsHub Logo
Post# of 252780
Next 10
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

Re: None

Wednesday, 06/27/2007 4:08:43 PM

Wednesday, June 27, 2007 4:08:43 PM

Post# of 252780
JAV

JAV trying to rescue its stock price from the doldrums. I personally can't figure out what it's doing way down at ~$6.20.

Javelin Pharmaceuticals to Host Conference Call on Recent Major Milestones
BusinessWire - June 27, 2007 3:35 PM ET

Javelin Pharmaceuticals (AMEX: JAV) announced today that Dr. Daniel Carr, CEO and CMO, and members of Javelin's senior management will host a call on three recent milestones as well as progress in the clinical development of PMI-150 (intranasal ketamine). The call will be held tomorrow June 28, 2007 at 8:30 a.m. EDT.

Recent milestones include recently reported top line results for Javelin's Phase 3 pivotal trial of Rylomine (intranasal morphine), the ten year extension of European patent protection for Dyloject (injectable diclofenac) to 2024, and the selection of Javelin Pharmaceuticals by Russell Research for the Russell 2000(R), 3000(R), Micro-cap(TM) and Global Indexes.

The Company invites all interested parties to participate. The call will also be webcast and accessible live through the following URL: http://ir.javelinpharmaceuticals.com/events.cfm The call will be archived on the Company's website www.javelinpharmaceuticals.com.

CONFERENCE CALL ALERT

Javelin Pharmaceuticals, Inc. Conference Call

Date: June 28, 2007

Time: 8:30 a.m. E.D.T.

Please call: 1-800-289-0726 domestic callers OR international participants 1-913-981-5545

Javelin Participants: Daniel B. Carr, CEO and CMO; Fred Mermelstein, President; Steven J. Tulipano, CPA., CFO; David B. Bernstein, General Counsel and Chief IP Counsel; and Curtis Wright, IV, EVP, Risk Management and Regulatory Affairs.

About Javelin Pharmaceuticals, Inc.:

With US corporate headquarters in Cambridge, MA, and a European office in Cambridge, UK, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit www.javelinpharmaceuticals.com.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.